Our T1D Family: The Eyth's

Like many parents, AJ & Emily Eyth were worried about their daughters’ risk to develop type 1 diabetes because AJ lives with the disease. After 5 years participating in TrialNet’s monitoring program, Kaley developed her third autoantibody which made her eligible to enroll in the TrialNet Abatacept Prevention study at the age of 9.